Institution
New York University
Education•New York, New York, United States•
About: New York University is a education organization based out in New York, New York, United States. It is known for research contribution in the topics: Population & Poison control. The organization has 72380 authors who have published 165545 publications receiving 8334030 citations. The organization is also known as: NYU & University of the City of New York.
Topics: Population, Poison control, Context (language use), Health care, Cancer
Papers published on a yearly basis
Papers
More filters
••
2,002 citations
••
TL;DR: A more fruitful integrative paradigm of "sustaincentrism" is then articulated, and implications for organizational science are generated as if sustainability, extended community, and our Academy mattered as discussed by the authors.
Abstract: Modern management theory is constricted by a fractured epistemology. which separates humanity from nature and truth from morality. Reintegration is necessary if organizational science is to support ecologically and socially sustainable development. This article posits requisites of such development and rejects the paradigms of conventional technocentrism and antithetical ecocentrism on grounds of incongruence. A more fruitful integrative paradigm of “sustaincentrism” is then articulated, and implications for organizational science are generated as if sustainability, extended community, and our Academy mattered.
1,993 citations
••
TL;DR: A large-scale screen is described to create an atlas of CNS gene expression at the cellular level, and to provide a library of verified bacterial artificial chromosome vectors and transgenic mouse lines that offer experimental access to CNS regions, cell classes and pathways.
Abstract: The mammalian central nervous system (CNS) contains a remarkable array of neural cells, each with a complex pattern of connections that together generate perceptions and higher brain functions. Here we describe a large-scale screen to create an atlas of CNS gene expression at the cellular level, and to provide a library of verified bacterial artificial chromosome (BAC) vectors and transgenic mouse lines that offer experimental access to CNS regions, cell classes and pathways. We illustrate the use of this atlas to derive novel insights into gene function in neural cells, and into principal steps of CNS development. The atlas, library of BAC vectors and BAC transgenic mice generated in this screen provide a rich resource that allows a broad array of investigations not previously available to the neuroscience community.
1,989 citations
••
TL;DR: The central roles of macrophages in each of the stages of disease pathogenesis are discussed, including atherosclerosis, stroke, and sudden cardiac death.
1,986 citations
••
Vanderbilt University1, University of Texas MD Anderson Cancer Center2, University of Pennsylvania3, University of Colorado Denver4, New York University5, University of South Florida6, Peter MacCallum Cancer Centre7, Baylor University Medical Center8, University of Pittsburgh9, Harvard University10, University of Newcastle11, University of California, Los Angeles12, Hoffmann-La Roche13, Veterans Health Administration14, Plexxikon15
TL;DR: Vemurafenib induces clinical responses in more than half of patients with previously treated BRAF V600-mutant metastatic melanoma, and the median overall survival in this study with a long follow-up was approximately 16 months.
Abstract: Approximately 50% of melanomas harbor activating (V600) mutations in the serine– threonine protein kinase B-RAF (BRAF). The oral BRAF inhibitor vemurafenib (PLX4032) frequently produced tumor regressions in patients with BRAF V600– mutant metastatic melanoma in a phase 1 trial and improved overall survival in a phase 3 trial. METHODS We designed a multicenter phase 2 trial of vemurafenib in patients with previously treated BRAF V600–mutant metastatic melanoma to investigate the efficacy of vem urafenib with respect to overall response rate (percentage of treated patients with a tumor response), duration of response, and overall survival. The primary end point was the overall response rate as ascertained by the independent review committee; overall survival was a secondary end point. RESULTS A total of 132 patients had a median follow-up of 12.9 months (range, 0.6 to 20.1). The confirmed overall response rate was 53% (95% confidence interval [CI], 44 to 62; 6% with a complete response and 47% with a partial response), the median duration of response was 6.7 months (95% CI, 5.6 to 8.6), and the median progression-free survival was 6.8 months (95% CI, 5.6 to 8.1). Primary progression was observed in only 14% of patients. Some patients had a response after receiving vemurafenib for more than 6 months. The median overall survival was 15.9 months (95% CI, 11.6 to 18.3). The most common adverse events were grade 1 or 2 arthralgia, rash, photosensitivity, fatigue, and alopecia. Cutaneous squamous-cell carcinomas (the majority, keratoacanthoma type) were diagnosed in 26% of patients. CONCLUSIONS Vemurafenib induces clinical responses in more than half of patients with previously treated BRAF V600–mutant metastatic melanoma. In this study with a long follow-up, the median overall survival was approximately 16 months. (Funded by Hoffmann–La Roche; ClinicalTrials.gov number, NCT00949702.)
1,986 citations
Authors
Showing all 73237 results
Name | H-index | Papers | Citations |
---|---|---|---|
Rob Knight | 201 | 1061 | 253207 |
Virginia M.-Y. Lee | 194 | 993 | 148820 |
Frank E. Speizer | 193 | 636 | 135891 |
Stephen V. Faraone | 188 | 1427 | 140298 |
Eric R. Kandel | 184 | 603 | 113560 |
Andrei Shleifer | 171 | 514 | 271880 |
Eliezer Masliah | 170 | 982 | 127818 |
Roderick T. Bronson | 169 | 679 | 107702 |
Timothy A. Springer | 167 | 669 | 122421 |
Alvaro Pascual-Leone | 165 | 969 | 98251 |
Nora D. Volkow | 165 | 958 | 107463 |
Dennis R. Burton | 164 | 683 | 90959 |
Charles N. Serhan | 158 | 728 | 84810 |
Giacomo Bruno | 158 | 1687 | 124368 |
Tomas Hökfelt | 158 | 1033 | 95979 |